Results and Lessons Learned from CapacityPlus 2009-2015
Reporting period: January 2008-December 2010
Accessed: 29.09.2019
Russian Federation
Accessed: 24.09.2019
Reporting Period 2010-2011
(Published with Decision No. 3003/QðBYT dated 19/8/2009 of the Minister of Health)
The guidelines are primarily intended for health-care professionals working in first- or second-level health-care facilities, including emergency, inpatient and outpatient services. They are also directed at policy-makers, health-care planners and programme managers, academic institutions, non-gover...nmental and civil society organizations to inform capacity-building, teaching and research agendas.
Web annex A provides the quantitative evidence reports, Web annex B summarizes the qualitative and economic evidence and Web annex C presents the Evidence-to-Decision frameworks.
more
4th edition, Reference Manual
Fragile Beginnings. The Fragile Beginnings series examines the growing body of research on the unique vulnerabilities of children: in utero and at birth, during infancy and childhood and throughout adolescence. Its purpose is to enable evidence-based advocacy and action on children’s environmental... health
more
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic tests (RDTs) for individuals initiating or continuing long-acting injectable PrEP, such as LEN and long acting injectable cabotegravir (CAB-LA). Flexible HIV testing approaches are essential for ensuring that testing does not become a barrier to accessing or continuing PrEP, including long-acting injectable options.
more
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B